Status:
ENROLLING_BY_INVITATION
FibroScan-Reproducibility and Repeatability Study
Lead Sponsor:
Echosens
Conditions:
Non-Alcoholic Fatty Liver Disease
Liver Disease; Alcohol-Related
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Chronic liver disease (CLD) is a serious health issue worldwide, often progressing without symptoms until advanced stages with risks of complications like liver cancer and cirrhosis. Early detection i...
Eligibility Criteria
Inclusion
- Adult patients (age ≥ 18 y.o) with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), Metabolic and Alcohol-related Liver Disease (MetALD), and Alcohol-related Liver Disease (ALD).
- Adult patients able to give written informed consent.
Exclusion
- Vulnerable patients
- Patients with other chronic liver disease including but not limited to hepatitis B, hepatitis C, autoimmune hepatitis, cholestatic diseases
- Patients with ascites
- Patients with elevated conjugated bilirubin (\>1.5 ULN)
- Patients with heart failure
Key Trial Info
Start Date :
July 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT06877026
Start Date
July 19 2025
End Date
December 31 2025
Last Update
July 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King's College Hospital NHS Foundation Trust
London, England, United Kingdom, SE5 9RS